Higher Drug Prices from Anticompetitive Conduct: Three Case Studies.
J Leg Med
; 39(2): 151-167, 2019.
Article
de En
| MEDLINE
| ID: mdl-31503532
ABSTRACT
U.S. consumers pay high drug prices. Brand-name drug companies claim that these prices are justified by pathbreaking research and development. But, sometimes the prices result from anticompetitive conduct. This article offers three case studies of how such behavior can increase price based on wakefulness drug Provigil, the allergic-reaction-treating EpiPen, and infection-treating Daraprim. The article contends that behavior that makes no sense other than by harming a competitor, that undercuts a regulatory regime, or that involves collusive conduct should not be protected. In targeting this behavior, antitrust scrutiny promises to lower drug prices.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pyriméthamine
/
Coûts des médicaments
/
Frais pharmaceutiques
/
Modafinil
Type d'étude:
Health_economic_evaluation
Limites:
Humans
Pays/Région comme sujet:
America do norte
Langue:
En
Journal:
J Leg Med
Année:
2019
Type de document:
Article